The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...

Novo Nordisk shares rose Friday after the FDA granted accelerated approval for Wegovy to treat liver fibrosis in adults, ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.